Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

PURPOSE: T cells can be genetically modified to express an anti-CD19 chimeric antigen receptor (CAR). We assessed the safety and efficacy of administering autologous anti-CD19 CAR T cells to patients with advanced CD19(+) B-cell malignancies. PATIENTS AND METHODS: We treated 15 patients with advance...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Oncol
Auteurs principaux: Kochenderfer, James N., Dudley, Mark E., Kassim, Sadik H., Somerville, Robert P.T., Carpenter, Robert O., Stetler-Stevenson, Maryalice, Yang, James C., Phan, Giao Q., Hughes, Marybeth S., Sherry, Richard M., Raffeld, Mark, Feldman, Steven, Lu, Lily, Li, Yong F., Ngo, Lien T., Goy, Andre, Feldman, Tatyana, Spaner, David E., Wang, Michael L., Chen, Clara C., Kranick, Sarah M., Nath, Avindra, Nathan, Debbie-Ann N., Morton, Kathleen E., Toomey, Mary Ann, Rosenberg, Steven A.
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2015
Sujets:
ORIGINAL REPORTS
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4322257/
https://ncbi.nlm.nih.gov/pubmed/25154820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.56.2025
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires